Follow the Pundits: When Institutional Trades Matter | Funanc1al – tagged "Parkinson’s disease"

Follow the Pundits

Tag: Parkinson’s disease

Investor hiker climbing a brain-shaped Acadia National Park trail marked by biotech milestones, symbolizing ACADIA Pharmaceuticals’ growth potential.

July 9, 2025

ACADIA Pharmaceuticals: Biotech Powerhouse Baker Bros Still Believes. Should You Buy In?

Biotech heavyweight Baker Bros still owns over 25% of ACADIA Pharmaceuticals (ACAD), and the stock is heating up. With expanding revenue, a rich CNS pipeline, and smart money backing it, is this the comeback story investors have been waiting for?

Read entire article

Tags: ACAD, ACADIA Pharmaceuticals, Baker Bros, Biotech Investing, Biotech Stocks, Funanc1al, Funanc1al Contrarian Picks, Funanc1al for Investors, Funanc1al Investing, Funanc1alBiotech, Funanc1alEdge, Funanc1alFinance, Funanc1alFun, Funanc1alHumor, Funanc1alInsiders, Funanc1alInvesting, Funanc1alMentalHealth, Funanc1alPharma, Funanc1alStocks, Growth Investing, Hedge Funds Investing, High-Conviction Investing, insider holdings, Parkinson’s disease, pharma pipeline, Rett Syndrome

Your cart

Follow the Pundits

Tag: Parkinson’s disease

July 9, 2025

ACADIA Pharmaceuticals: Biotech Powerhouse Baker Bros Still Believes. Should You Buy In?

Quick links

Contact us

About us

Follow us